Prostate Cancer Treatment Market Research Report Information By Drug Class (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE

6.1. Overview

6.2. Hormonal Therapy

6.3. Chemotherapy

6.4. Immunotherapy

6.5. Targeted Therapy

6.6. Others

7. PROSTATE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL

7.1. Overview

7.2. Hospital Pharmacies

7.3. Drug Stores & Retail Pharmacies

7.4. Online Pharmacies

8. PROSTATE CANCER TREATMENT MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Prostate Cancer Treatment Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Prostate Cancer Treatment Market,

9.7. Key developments and Growth Strategies

9.7.1. New Drug TypeLaunch/Service Deployment

9.7.2. Merger &Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income,2022

9.8.2. Major Players R&D Expenditure.2022

10. COMPANY PROFILES

10.1. Johnson & Johnson;

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Drug Types Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Services Inc.;

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Drug Types Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Astellas Pharma Inc.;

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Drug Types Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Eli Lilly and Company;

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Drug Types Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Sanofi;

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Drug Types Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Ipsen Pharma;

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Drug Types Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Bayer AG;

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Drug Types Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. AstraZeneca;

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Drug Types Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. Valeant Pharmaceuticals International, Inc.;

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Drug Types Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Merck & Co., Inc.;

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Drug Types Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

10.11. Pfizer Inc;

10.11.1. Company Overview

10.11.2. Financial Overview

10.11.3. Drug Types Offered

10.11.4. Key Developments

10.11.5. SWOT Analysis

10.11.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 PROSTATE CANCER TREATMENT MARKET, SYNOPSIS, 2018-2032

TABLE 2 PROSTATE CANCER TREATMENT MARKET, ESTIMATES &FORECAST, 2018-2032(USD BILLION)

TABLE 3 PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 4 PROSTATE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: PROSTATE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 US: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 8 US: PROSTATE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 CANADA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 10 CANADA: PROSTATE CANCER TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 1 EUROPE: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 2 EUROPE: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 3 GERMANY: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE,2018-2032 (USD BILLION)

TABLE 4 GERMANY: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 5 FRANCE: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 6 FRANCE: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 7 ITALY: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 8 ITALY: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 9 SPAIN: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 10 SPAIN: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 11 UK: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 12 UK: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 17 JAPAN: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 18 JAPAN: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 19 CHINA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 20 CHINA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 21 INDIA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 22 INDIA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 23 AUSTRALIA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 24 AUSTRALIA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 33 AFRICA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 34 AFRICA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: PROSTATE CANCER TREATMENT MARKET,BY DRUG TYPE, 2018-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: PROSTATE CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE PROSTATE CANCER TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE PROSTATE CANCER TREATMENT MARKET

FIGURE 4 PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY DRUG TYPE, 2022

FIGURE 5 PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY DISTRIBUTION CHANNEL, 2022

FIGURE 6 PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 7 NORTH AMERICA: PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 8 EUROPE: PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 ASIA-PACIFIC: PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 REST OF THE WORLD: PROSTATE CANCER TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 PROSTATE CANCER TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 12 JOHNSON & JOHNSON: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 JOHNSON & JOHNSON: SWOT ANALYSIS

FIGURE 14 SERVICES INC.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 SERVICES INC.:SWOT ANALYSIS

FIGURE 16 ASTELLAS PHARMA INC.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ASTELLAS PHARMA INC.:SWOT ANALYSIS

FIGURE 18 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 ELI LILLY AND COMPANY:SWOT ANALYSIS

FIGURE 20 SANOFI:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 SANOFI:SWOT ANALYSIS

FIGURE 22 IPSEN PHARMA:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 IPSEN PHARMA:SWOT ANALYSIS

FIGURE 24 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 BAYER AG: SWOT ANALYSIS

FIGURE 26 ASTRAZENECA:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 ASTRAZENECA:SWOT ANALYSIS

FIGURE 28 VALEANT PHARMACEUTICALS INTERNATIONAL, INC.:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 VALEANT PHARMACEUTICALS INTERNATIONAL, INC.:SWOT ANALYSIS

FIGURE 30 MERCK & CO., INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 MERCK & CO., INC.:SWOT ANALYSIS

FIGURE 32 PFIZER INC:FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 PFIZER INC:SWOT ANALYSIS